Trials / Completed
CompletedNCT02344615
Nerve Stimulator Versus Ultrasound-guided Infraclavicular Block
A Randomized Comparison of Nerve Stimulator and Ultrasound-guided Infraclavicular Block for Upper Extremity Surgery
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Cheju Halla General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The investigators compared the postoperative analgesia of nerve stimulator-guided and ultrasound-guided infraclavicular block for upper extremity surgery.
Detailed description
Ultrasound (US)-guided peripheral nerve block has increased in popularity. It has many advantages such as improved success rate, faster onset time, fewer needle passes, shorter performance time, and reduced procedural pain and vascular puncture. However, there is no information about postoperative analgesia. Therefore, the investigators tested whether ultrasound-guided peripheral nerve block enhanced the postoperative analgesia for upper extremity surgery compared with nerve stimulator (NS) guidance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | NS-guided infraclavicular block | Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used. |
| PROCEDURE | US-guided infraclavicular block | Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-01-26
- Last updated
- 2016-01-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02344615. Inclusion in this directory is not an endorsement.